[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].C([N:15]1[CH2:20][CH2:19][CH:18]([NH:21][C:22]2[N:30]=[C:29]3[C:25]([N:26]=[CH:27][N:28]3[C@@H:31]3[CH2:35][C@H:34]([N:36]4[CH:40]=[C:39]([CH2:41][OH:42])[CH:38]=[N:37]4)[C@@H:33]([OH:43])[C@H:32]3[OH:44])=[C:24]([NH:45][CH2:46][CH:47]([C:54]3[CH:59]=[CH:58][CH:57]=[CH:56][CH:55]=3)[C:48]3[CH:53]=[CH:52][CH:51]=[CH:50][CH:49]=3)[N:23]=2)[CH2:17][CH2:16]1)C1C=CC=CC=1.C([O-])=O.[NH4+]>C(O)C.[OH-].[Pd+2].[OH-]>[F:1][C:2]([F:7])([F:6])[C:3]([OH:5])=[O:4].[C:54]1([CH:47]([C:48]2[CH:49]=[CH:50][CH:51]=[CH:52][CH:53]=2)[CH2:46][NH:45][C:24]2[N:23]=[C:22]([NH:21][CH:18]3[CH2:17][CH2:16][NH:15][CH2:20][CH2:19]3)[N:30]=[C:29]3[C:25]=2[N:26]=[CH:27][N:28]3[C@@H:31]2[CH2:35][C@H:34]([N:36]3[CH:40]=[C:39]([CH2:41][OH:42])[CH:38]=[N:37]3)[C@@H:33]([OH:43])[C@H:32]2[OH:44])[CH:59]=[CH:58][CH:57]=[CH:56][CH:55]=1(1R,2S,3R,1S)-3-[2-(1-benzyl-piperidin-4-ylamino)-6-(2,2-diphenyl-ethylamino)-purin-9-yl]-5-(4-hydroxymethyl-pyrazol-1-yl)-cyclopentane-1,2-diol trifluoroacetate (Example 78) (50 mg, 0.063 mmol) is dissolved in ethanol (2 ml). Palladium hydroxide (20% on carbon) (45 mg, 0.57 mmol) and ammonium formate (20 mg, 0.057 mmol) are added and the reaction mixture is refluxed for 1.5 hours. The reaction mixture is allowed to cool, the catalyst is filtered off and the solvent is removed in vacuo. The title compound is obtained after purification by reverse phase column chromatography (Isolute™ C18, 0-100% MeCN in water—0.1% TFA). MS (ES+) m/e 610 (MH+).
Loading…